Investors & Media

Welcome to the Investor Relations and Public Relations division of Medigene AG. This is where you will find current information on a variety of subjects, including Medigene AG shares, company news, financial reports and key figures.

Latest News

Medigene achieves positive preliminary results in Phase I of Phase I/II trial of TCR-T therapy MDG1011 in blood cancers


New safety data shows Medigene's inducible system produces correctly-paired T cell receptors only


Medigene, IRICoR, and University of Montréal expand analyses of potentially novel cancer antigens


The Medigene Share

The Medigene share MDG1 (ISIN:DE000A1X3W00 ) is listed at the Frankfurt Stock Exchange since June 2000. 

show medigene share


22 - 24 Feb 2022

Next Generation CAR-TCR Summit

23 Mar 2022

Annual Report 2021

04 May 2022

Quarterly Statement Q1 2022

18 May 2022

Annual General Meeting 2022

03 Aug 2022

6-Months Report 2022

07 - 08 Sep 2022

Stifel London Cross Sector Insight Conference

02 Nov 2022

Quarterly Statement Q3 2022

Corporate Governance

Good corporate governance is the basis of our decision-making and monitoring processes. It stands for responsible and value-based leadership and control of the Company for long-term success, goal-oriented and efficient cooperation between the Executive Board and Supervisory Board, respect for the interests of our shareholders and employees, consistently transparent and responsible corporate decisions and an appropriate risk management system.

read more

press photos

Laboratory work

DownLoad (9 MB)

Laboratory work (6)

Cell culture work

DownLoad (4 MB)

Laboratory work (7)

Cell sorting

DownLoad (353 KB)

Contact person

Dr. Anna Niedl
Vice President Investor Relations & Corporate Communications
Phone: +49 89 2000 3333 01
Fax: +49 89 2000 33 2920